Toxic Product Exposure | Toxic Housing Products

Asbestos News

UK Health Regulator Rejects Mesothelioma Drug

RSS News Feeds
Toxic Products & Environmental Exposures
Lung Cancer
Asbestosis
Asbestos
Mesothelioma
 All RSS Feeds

At a glance:

The British National Health Service's cost-control unit, "NICE", will discontinue funding a mesothelioma drug, pemetrexed (Alimta) in England and Wales. 
 
The drug's maker, Eli Lilly, contends that the drug is an effective therapy for a difficult-to-treat cancer caused almost completely by workplace exposure to asbestos. It will appeal the decision. 
 
A cancer advocacy group also criticized the move, saying since the drug is available in Scotland, the decision is not equitable. 
 

UK's NICE Rejects Lilly's Alimta in Mesothelioma

Cancerpage.com - 6/27/2006 8:23 AM


 
LONDON JUN 26, 2006 (Agence de Presse Medicale for Reuters Health) - UK cost-effectiveness watchdog, NICE, has rejected Eli Lilly's Alimta (pemetrexed) for treating mesothelioma, the local arm of the U.S. company said on Monday.
 
In a statement timed to tie in with the anticipated announcement of the rejection by NICE, Lilly UK said: "NICE has recommended a ban on people with an asbestos-induced cancer, mesothelioma, receiving the only licensed medicine for the disease.
 
· Read The Full Asbestos Article From Cancerpage.com -->

· Read All Asbestos News Stories -->

Comments On Asbestos News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: